Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Jul 1;47(1):102-4.
doi: 10.1086/588791.

A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy

Jason B Dinoso  1 , Scott Y Kim, Robert F Siliciano, Joel N Blankson
Affiliations
Comparative Study

A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy

Jason B Dinoso et al. Clin Infect Dis. .

Abstract

Elite suppressors are untreated individuals with human immunodeficiency virus type 1 (HIV-1) infection who maintain viral loads <50 copies/mL. Using a single-copy assay, we show that there is no statistically significant difference between the proportions of elite suppressors and patients receiving suppressive highly active antiretroviral therapy who have viral loads of <1 copy/mL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Viral load (VL) measurements. Open symbols represent undetectable viral loads (< 1 copy/mL). A, Single viral load measurements in elite suppressors (red) and HAART-treated individuals (blue). B, Two viral load measurements. Viral loads from 6 elite suppressors were measured in 2 separate blood samples obtained a mean of 8.6 months apart. C, Longitudinal analysis of elite suppressor viral loads in 4 separate blood samples obtained from patient ES13 (circles) and 8 separate blood samples obtained from patient ES8 (triangles). c, Copies.
See this image and copyright information in PMC

References

    1. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–91. - PubMed
    1. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA. 2001;286:196–207. - PubMed
    1. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441–57. - PMC - PubMed
    1. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol. 2006;80:4758–70. - PMC - PubMed
    1. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1–infected HLA–B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 2006;203:1357–69. - PMC - PubMed

Publication types